DATA Globaldata Plc

RNS Number:7573I
Provalis PLC
18 February 2005


For Immediate Release                      18th February 2005


                                  Provalis plc

                                 Board Changes

     Appointment of Dr Alan Aikman, and retirement of Dr David Bloxham, as
                            Non-Executive Directors

Provalis plc (LSE: PRO; NASDAQ: PVLS), the International Medical Diagnostics and
Pharmaceuticals Group, is pleased to announce that it appointed Dr Alan Aikman
as a non-executive Director on 17th February 2005.

Dr Aikman, aged 57, an experienced Healthcare business consultant, is currently
a non-executive director of both listed and unlisted Healthcare companies.  He
is a non-executive director of Theratase plc and is the non-executive Chairman
of Niagara Healthcare Ltd and Vibrant Medical Ltd.  He has also been an
executive Director of Smith and Nephew Healthcare and Palmer Bio-Science Ltd. Dr
Aikman, who has a Ph.D in biochemistry, began his career in marketing and
pharmaceutical product management at GD Searle both in the UK and USA.

At the same time, Dr David Bloxham announced that he will retire from the Board
on 31st May 2005, after five years with the Company.  David's insight has proved
invaluable in helping Provalis to focus, and then successfully partner, the
vaccine business and to develop its US sales strategy for the Medical
Diagnostics business that has now been implemented.

Frank Harding, Chairman of Provalis, said, "I welcome this opportunity of
thanking David for his significant contribution to the Group's strategic
development and wish him well for the future.

At the same time, I am delighted to welcome Alan to the Board. His international
marketing and commercial experience in a broad range of Healthcare businesses
will be invaluable to Provalis as it expands the direct marketing and sale of
its products in world markets."

                                      END

Provalis' Website; http://www.provalis.com

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of
1995: Statements in this announcement that relate to future plans, expectations,
events, performances and the like are forward-looking statements as defined in
the US Private Securities Litigation Reform Act of 1995. Actual results of
events could differ materially from those described in the forward-looking
statements due to a variety of factors.  Such factors include, among others: the
viability of the Group's products, which are at various stages of development;
the generation of sufficient operating cash flow by the Group's pharmaceutical
and medical diagnostic businesses to finance the ongoing development of these
businesses as well as the Group's research and development activities; the
success of the Group's research and development strategy and activities;
uncertainties related to future clinical trial results and the associated
regulatory process; the execution and success of collaborative agreements with
third parties; availability and level of reimbursement for the Group's products
from government health administration authorities or other third-party payors;
the rate of net cash utilisation within the Group and, hence, the Group's
possible need for additional capital in the short, medium and/or long term; the
Group's intellectual property position and the success of patent applications
for its products and technologies; the Group's dependence on key personnel;
general business and economic conditions; the impact of future laws, regulations
and policies; stock market trends in the Group's sector; and other factors
beyond the Group's control that may cause the Group's available capital
resources to be used more quickly than expected.  These and other factors that
could affect the Company's future results are more fully described in its
filings with the US Securities and Exchange Commission, in particular the latest
20-F filing, copies of which are available from the Company Secretary at the
Company's registered address.


For further information:-

Dr Phil Gould, Chief Executive Officer, Provalis plc     Tel:  01244 833463
Mr Peter Bream, Finance Director, Provalis plc           Tel:  01244 833552
Mr Lee Greenbury, Company Secretary, Provalis plc        Tel:  01244 833402
Lisa Baderoon, Buchanan Communications                   Tel:  020 7466 5000


Notes to Editors


Provalis plc (LSE: PRO; NASDAQ: PVLS) is an international healthcare group with
two operating businesses:-


* Medical Diagnostics - develops medical diagnostic products
  for chronic disease management for sale to world markets. The business'
  principal products are in2it(TM) A1c and Glycosal(R), both diabetes diagnostic 
  tests, and Osteosal(R), a diagnostic test for osteoporosis.

* Pharmaceuticals - sells and markets its own, and third
  party, branded, prescription medicines in the UK and Ireland to GPs and
  hospitals through its regionally managed sales force. The business' principal
  product is Diclomax(R), a medicine for use in the treatment of 
  musculo-skeletal disorders, and it also sells products in the areas of 
  osteoporosis, migraine and dermatology.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BOATRMFTMMABBAA

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024